Does the use of the checkpoint inhibitor nivolumab affect the outcomes of transplant?
Carmelo Carlo Stella
History of gene therapies
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver
Oncogenic mutational networks in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)
Gerrit Jan Schuurhuis